Jeremy Abramson, MD, from the Massachusetts General Hospital, Massachusetts, MA, gives an overview of the interim analysis of a multicenter prospective Phase II study of Dose-Adjusted EPOCH-R (NCT01092182), which showed that the vast majority of patients with Burkitt’s Lymphoma achieved complete remission with the DA-EPOCH-R based therapy. The results were presented at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL.